Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocannabinoid modulation of a reciprocal fronto-coerulear connection in contextual discrimination.

Cell reports·2026
Same author

Distinct endocannabinoids specifically signal to astrocytes or neurons in the adult mouse hippocampus.

Nature neuroscience·2025
Same author

Central amygdalar PKCδ neurons mediate fentanyl withdrawal.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2025
Same author

Effects of 4-Month Methylphenidate Treatment on Functional Connectivity in Attention-Deficit Hyperactivity Disorder.

medRxiv : the preprint server for health sciences·2025
Same author

High ovarian hormones present during fear extinction reduce fear relapse through a nigrostriatal dopamine pathway.

Biology of sex differences·2025
Same author

Dorsomedial Striatum (DMS) CB1R Signaling Promotes Pavlovian Devaluation Sensitivity in Male Long Evans Rats and Reduces DMS Inhibitory Synaptic Transmission in Both Sexes.

eNeuro·2025

Related Experiment Video

Updated: May 16, 2026

An Automated T-maze Based Apparatus and Protocol for Analyzing Delay- and Effort-based Decision Making in Free Moving Rodents
07:42

An Automated T-maze Based Apparatus and Protocol for Analyzing Delay- and Effort-based Decision Making in Free Moving Rodents

Published on: August 2, 2018

Cannabinoids and value-based decision making: implications for neurodegenerative disorders.

Angela M Lee1, Erik B Oleson, Leontien Diergaarde

  • 1Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU university medical center, Amsterdam, the Netherlands.

Basal Ganglia
|November 20, 2012
PubMed
Summary

Cognitive impairments, especially in value-based decision making, are common in Parkinson's Disease (PD). The cannabinoid system influences dopamine, impacting PD symptoms and offering potential therapeutic targets.

More Related Videos

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

Related Experiment Videos

Last Updated: May 16, 2026

An Automated T-maze Based Apparatus and Protocol for Analyzing Delay- and Effort-based Decision Making in Free Moving Rodents
07:42

An Automated T-maze Based Apparatus and Protocol for Analyzing Delay- and Effort-based Decision Making in Free Moving Rodents

Published on: August 2, 2018

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

Area of Science:

  • Neuroscience
  • Cognitive Science
  • Pharmacology

Background:

  • Cognitive dysfunction is a key symptom in neurodegenerative diseases like Parkinson's Disease (PD).
  • Value-based decision making, an executive function, is impaired in PD and involves shared neural pathways in the basal ganglia and dopamine system.
  • The endogenous cannabinoid system modulates dopamine function, influencing decision-making processes.

Purpose of the Study:

  • To review interdisciplinary research on value-based decision making and dopamine's role in PD.
  • To explore the modulatory effects of the cannabinoid system on dopamine and decision-making.
  • To discuss implications for PD symptomatology and treatment.

Main Methods:

  • Literature review of interdisciplinary research.
  • Analysis of reinforcement learning theories related to dopamine.
  • Examination of animal and human studies on cannabinoid receptor agonists and ligands.

Main Results:

  • Value-based decision making is impaired in Parkinson's Disease.
  • Dopamine and the basal ganglia are critical for value-based decision making.
  • Cannabinoid system activation modulates dopamine function and decision-making.

Conclusions:

  • The cannabinoid system presents a potential therapeutic target for cognitive symptoms in Parkinson's Disease.
  • Understanding cannabinoid modulation of dopamine is crucial for PD treatment strategies.
  • Further research into cannabinoid-based interventions may alleviate cognitive deficits in PD.